Physician profile
Jonathan Patrick Staidle
NPI 1982994455
$3,185.46
in general payments reported to CMS, 2019-2025
22 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $413 · 2021: $324 · 2022: $459 · 2023: $298 · 2024: $622 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.89 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.48 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $490.19 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $242.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $213.09 | 2023-2025 | |
| Amgen INC. | $201.67 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $148.33 | 2021-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $130.75 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $119.77 | 2022-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.27 | 2020-2025 | Jublia, Cabtreo |
| Pfizer INC. | $79.11 | 2019-2025 | |
| Genzyme Corporation | $62.98 | 2023 | |
| Dermira, INC. | $48.77 | 2020-2021 | |
| Galderma Laboratories, L.P. | $46.44 | 2019-2025 | Nemluvio |
| Ucb, INC. | $30.83 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $27.18 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.43 | 2019 | |
| Almirall LLC | $23.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.20 | 2021 | |
| Mission Pharmacal Company | $12.81 | 2019 | |
| Genentech USA, INC. | $12.80 | 2020 | |
| Smith+Nephew, INC. | $12.77 | 2023 | Grafix |
| Prugen, INC. Pharmaceuticals | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Staidle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.